Kamil Ali-Jackson

Kamil Ali-Jackson is a declared insider at 3 companies (senior executive); the most frequent names are Rigel Pharmaceuticals Inc, Aclaris Therapeutics, Inc. and PDS Biotechnology Corp. We count 14 filings; the first trade dates from 11 March 2021 and the latest from 22 June 2026.

Both buying and selling appear: 1 purchase worth €82k, against 3 sales worth €234k. The amount is not disclosed for 1 filing. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 5 share grants and 4 option exercises. In 2026 alone, the filings show no purchases and 2 sales.

Most recently, on 24 June 2026, the filings show an open-market sale in Rigel Pharmaceuticals Inc. The clock since the last published purchase (17 June 2021) now reads 1,949 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.